YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Inactivation of the Muscarinic Receptor Subtype by Dibenamine

디벤아민에 의한 무스카린 수용체 아형의 불활성화

  • Published : 1995.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Dibenamine inhibited [$^{3}$H]quinuclidinyl benzilate ([$^{3}$H]QNB) binding in both concentration and incubation time-dependent manners. The $IC_{50}$/ value of dibenamine for the inhibition of the specific binding of 100 pM [$^{3}$'H]QNB following incubation of cerebral microsomes with dibenamine at 37.deg. C for 15 min was 20.mu.M. Dibenamine irreversibly decreased the binding site concentration for [$^{3}$H]QNB binding without affecting the affinity of [$^{3}$H]QNB for the muscarinic receptor. Analysis of the pirenzepine inhibition curve of [$^{3}$H]QNB binding to cerebral microsomes indicated the presence of two receptor subtypes with high(M$_{1}$ receptor, Ki=5nM) and low (M$_{2}$ receptor, Ki=160nM) affinity for pirenzepine. However, dibenamine(20.mu.M) treatment under the condition employed in these experiments caused steepening of the pirenzepine competition curve. The Ki value for pirenzepine in dibenamine treated-microsomes was approximately 120nM. suggesting a selective decrease in the number of M$_{1}$ receptor. Although dibenamine also inhibited [$^{3}$H]QNB binding to ventricular microsomes with $IC_{50}$/ value of 120.mu.M, the sensitivity for dibenamine in the ventricle was much lower than that in the cerebrum. These results indicate that dibenamine at low concentrations welectively inactivates the muscarinic M$_{1}$ receptor.

Keywords

References

  1. The Pharmacological Basis of Therapeutics(8th ed.) Neurohumoral transmission :The autonomic and somatic motor nervous systems Lefkowitz,R.J.;Hoffman,B.B.;Taylor,P.;A.G.Gilman(ed.);T.W.Rall(ed.);A.S.Nies(ed.);P.Taylor(ed.)
  2. Nature(Lond.) v.283 Pirenzepine distinguishes between different subclasses of muscarinic receptors Hammer,R.;Berrie,C.P.;Birdsall,N.J.M.;Burgen,A.S.V.;Hulme,E.C.
  3. Life Sci. v.32 A unique regulatory profile and regional distribution of〔³H〕pirenzepine binding in rat provide evidence for distinct M₁and M₂muscarinic receptor subtypes Watson,M.;Yamamura,H.I.;Roeske,W.R.
  4. Pharmacol.Ther. v.58 Muscarinic receptors:Characterization.function and coupling Caulfield,M.
  5. Naunyn-Schmiedebergs Arch. Pharmacol. v.332 The cardioselectivity of himbacine:a muscarinic receptor antagonist Anwar-UI,S.;Gilani,H.;Cobbin,L.B.
  6. Eur. J. Pharmacol. v.144 Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with atropine and gallamine Melchiorre,C.;Angeli,P.;Lambrecht,G.;Mutschler,E.;Picchio,M.T.;Wess,J.
  7. Life Sci. v.38 Cardioselective profile of AF-DX 116,a muscarinic M₂receptor antagonist Giachetti,A.;Micheletti,R.;Montagna,E.
  8. The G-protein linked receptor. Facts Book Acetylcholine receptors Watson,S.;Arkinstall,S.
  9. Mol. Pharmacol. v.30 Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain Norman,A.B.;Creese,I.
  10. Mol. Pharmacol. v.30 Gallamine binding to muscarinic M₁and M₂receptors studied by inhibition of [³H]quinuclidinylbenzilate binding to rat brain membranes Burke,R.E.
  11. Eur. J. Pharmacol. v.19 2-Halo-genoethylamines and the role of $Ca^2+$ in adrenergic α-receptor activation in the rat vas deferens Swamy,V.C.;Triggle,D.J.
  12. Kobe J. Med. Sci. v.22 The irreversible inhibitory effect of phenoxybenzamine on the noradrenaline-,K-,and Ba-induced contractions of rat's isolated vas deferens, particularly in relation to Ca. Ogino,K.
  13. J. Formosan Med. Assoc. v.78 External calcium ions and the inhibitory action of dibenamine and phenoxybenzamine Liao,C.S.;Lin.S.H.;Su,C.W.;Su,C.Y.
  14. Mol. Pharmacol. v.17 The effect of desensitization on the antagonism of the histamine response by phenoxybenzamine Kenakin,T.P.;Cook,D.A.
  15. Fundamental Concepts in Drug-Receptor Interactions Approaches to the quantitation and isolation of pharmacological receptors Moran,J.F.;Triggle,D.J.;Danielli,J.F.(ed.);Moran,J.F.(ed.);Triggle,D.J.(ed.)
  16. FEBS Lett. v.39 A novel approach to the question of allosteric properties or a receptor reserve' of drug binding sites of intestinal smooth muscle cells Kuhman-Clausen,D.
  17. Acta Biol. Med. Germ. v.34 The allosteric influence of β-haloalkylamines on the acetylcholine receptor of smooth muscle Morgenstern,R.;Winter,R.
  18. Mol. Pharmacol. v.20 Phenoxybenzamine and dibenamine interactions with calcium channel effectors of the muscarinic receptor El-Fakahany,E.;Richelson,E.
  19. Mol. Pharmacol. v.23 Affinity,efficacy,and stereoselectivity of oxotremorine analogues for muscarinic receptors in the isolated guinea pig ileum Ringdahl,B.;Jenden,D.J.
  20. J. Appl. Physiol. v.68 no.3 Muscarinic receptor reserve of airway smooth muscle and the response to isoproterenol Madison,J.M.
  21. J. Pharmacol. Methods v.7 A simple method for the purification of rat brain $Na^+$,$K^+$.-adenosine triphosphatase(ATPase) Mayrand,R.D.;Fullerton,D.S.;Ahmed,K.
  22. J. Biol. Chem. v.193 Protein measurement with the Folin Phenol reagent Lowry,O.H.;Rosebrough,N.J.;Farr,A.L.;Randall,R.J.
  23. Hypertension v.5 Decrease in $Na^+$,$K^+$,-ATPase activity and〔³H〕ouabain binding sites in sarcolemma prepared from hearts of spontaneously hypertensive rats Lee,S.W.;Schwartz,A.;Adams,R.J.;Yamori,Y.;Whitmer,K.;Lane,L.K.;Wallick,E.T.
  24. J. Biol. Chem. v.253 Effect of temperature on phosphorylation and ouabain binding to N-ethylmaleimide treated $Na^+$,$K^$+-ATPase Wallick,E.T.;Anner,B.M.;Ray,M.V.;Schwartz,A.
  25. Biochem. Pharmacol. v.22 Relationship between the inhibition constant(Ki) and the concentration of inhibitor which causes 50 percent inhibition$(IC_50)$of an enzymatic reaction Cheng,Y.C;Prusoff,W.H.
  26. Anal. Biochem. v.107 LIGAND:a versatile computerized approach for characterization of ligand binding system Munson,P.J.;Rodbard,D.
  27. Biochem. Pharmacol. v.36 Different agonist binding properties of M₁and M₂muscarinic receptors in calf brain cortex membranes Vanderheyden,P.;Ebinger,G.;Vauquelin,G.
  28. J. Pharmacol. Exp. Ther. v.228 Comparison of〔³H〕pirenzepine and〔³H〕quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain Luthin,G.R.;Wolfe,B.B.
  29. Eur. J. Pharmacol. v.131 Competitive interaction of pirenzepine with rat brain muscarinic acetylcholine receptors El-Fakahany,E.E.;Cioffi,C.L.;Abdellatif,M.M.;Miller,M.M.
  30. J. Pharmacol. Exp. Ther. v.242 Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M₁.M₂and M₃receptors Doods,H.N.;Mathy,M.J.;Davidesko,D.;VAN Charldorp,K.J.;DE Jonge,A.;VAN Zwieten,P.A.
  31. Br. J. Pharmacol. v.96 Affinity of muscarinic receptor antagonists for three putative muscarinic receptor binding sites Delmendo,R.E.;Michel,A.D.;Whiting,R.L.